NEW YORK (GenomeWeb News) – Foundation Medicine today said that it has signed a multi-year alliance with Eisai to conduct genomic profiling and diagnostic discovery for an oncology therapeutic candidate being developed by the Japanese drug firm.

The Cambridge, Mass.-based firm said that the goal of the collaboration is to prospectively identify specific genomic alterations in each patient's tumor. The results would be used for patient stratification, for guiding further drug development, and potentially for the commercialization of molecular diagnostic products.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Heads of various research funding agencies discuss how to encourage scientific breakthroughs, ScienceInsider reports.

The Kansas City Star examines issues surrounding newborn genome sequencing.

Researchers say their Research Resource Identifier citation format is catching on, Nature News reports.

In Science this week: the Human Silencing Hub protein complex, and more.